Skip to main content

Gilead asks FDA again to approve twice-a-year HIV-fighting drug

The drug, called lenacapavir, was rejected by the FDA in February because of issues with the vials holding the injectable drug.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.